We are live on ! Find out more
BLRX icon

BioLineRX
BLRX

15 hedge funds and large institutions have $10.7M invested in BioLineRX in 2014 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

224% more capital inflows, than outflows

Capital inflows: $2.59M | Capital outflows: $798K

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

0.17% more ownership

Funds ownership: 0.75% → 0.92% (+0.17%)

0% more funds holding

Funds holding: 15 → 15 (0)

Holders
15
Holders Change
–
Holders Change %
0%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$1.35M
2
Senvest Management
Senvest Management
New York
+$988K
3
Deutsche Bank
Deutsche Bank
Germany
+$189K
4
Morgan Stanley
Morgan Stanley
New York
+$24.3K
5
Cutter & Co Brokerage
Cutter & Co Brokerage
Missouri
+$14.8K

Top Sellers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
-$348K
2
Sphera Funds Management
Sphera Funds Management
Israel
-$298K
3
Renaissance Technologies
Renaissance Technologies
New York
-$147K
4
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$6.08K

BLRX Hedge Fund Activity: Q4 2014 in Review

15 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2014, worth a combined $10.7M — up 30% from $8.21M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new BLRX positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $1.35M. The largest seller was Opaleye Management, cutting an estimated $348K.

  • 15 institutional investors held BioLineRX (BLRX) as of Q4 2014, unchanged from Q3 2014.
  • Funds reported $10.7M of BioLineRX stock for Q4 2014, up 30% quarter-over-quarter.
  • 3 funds opened new BioLineRX positions in Q4 2014 and 2 closed out, a net change of +1 holder.
  • The largest BioLineRX buyer in Q4 2014 was Sabby Management, an estimated $1.35M added.
  • The largest BioLineRX seller in Q4 2014 was Opaleye Management, an estimated $348K sold.

Based on aggregated 13F filings for Q4 2014.